



## Medicine Supply Notification

MSN/2025/018

Apraclonidine (Iopidine<sup>®</sup>) 5mg/ml (0.5%) eye drops

Tier 2 – medium impact\*

Date of issue: 27/03/2025

Link: [Medicines Supply Tool](#)

### Summary

- Apraclonidine (Iopidine<sup>®</sup>) 5mg/ml (0.5%) eye drops are out of stock until early September 2025.
- Limited supplies of parallel imported apraclonidine (Iopidine<sup>®</sup>) 5mg/ml (0.5%) eye drops are available.
- Brimonidine 0.2% eye drops remain available and can support increased demand.
- Apraclonidine 10mg/ml (1%) preservative free unit dose eye drops remain available and can support increased demand.

### Actions Required

Where apraclonidine (Iopidine<sup>®</sup>) 5mg/ml (0.5%) eye drops are not available, clinicians in secondary care should:

- not initiate new patients on apraclonidine 5mg/ml (0.5%) eye drops;
- review existing patients to determine if this is still the most suitable therapy;
- consider prescribing brimonidine 0.2% eye drops, if appropriate, until the shortage has resolved, taking into account treatments the patient has previously tried, or
- if this is not suitable or not tolerated, consider prescribing apraclonidine (Iopidine<sup>®</sup>) 10mg/ml (1%) preservative free unit dose eye drops (off-label), and
- review local guidance on prescribing of apraclonidine 10mg/ml (1%) preservative free unit dose eye drops in primary care, and liaise with primary care colleagues, as needed.

Clinicians in primary care who are presented with a request for a further supply of apraclonidine 5mg/ml (0.5%) eye drops should seek advice from the patient's specialist on the most appropriate management option, if no communication has been issued locally.

Where alternative eye drops are prescribed, ensure the patient is not intolerant to any of the excipients and is counselled on the dosing regimen.

\*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

## Supporting information

Product	Apraclonidine 5mg/ml (0.5%) eye drops	Brimonidine 0.2% eye drops	Apraclonidine 10mg/ml (1%) preservative free unit dose eye drops*
Licensed indication	Short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery.	Reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension: as monotherapy in patients in whom topical beta-blocker therapy is contra-indicated, and as adjunctive therapy to other IOP lowering medications when target IOP is not achieved with a single agent.	Control or prevention of post-surgical elevations in IOP in patients after anterior segment laser surgery.
Dosage	One drop into affected eye(s) three times per day.	One drop into affected eye(s) twice daily.	One drop into eye scheduled for operation 1 hour before initiating anterior segment laser surgery. A second drop into same eye immediately upon completion of laser surgical procedure.

\*Red listed drug on most hospital formularies

### Links to further information

[SmPC apraclonidine \(lopidine®\) 5mg/ml eye drops](#)

[SmPC brimonidine 0.2% eye drops](#)

[SmPC apraclonidine \(lopidine®\) 1% eye drops unit dose preservative free](#)

[BNF apraclonidine](#)

## Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Specialist Pharmacy Service Regional Pharmacy Procurement Team, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands	Andi Swain	<a href="mailto:andi.swain@nhs.net">andi.swain@nhs.net</a>	Dav Manku	<a href="mailto:Dav.Manku@uhb.nhs.uk">Dav.Manku@uhb.nhs.uk</a>
East of England	James Kent	<a href="mailto:james.kent@nhs.net">james.kent@nhs.net</a>	Tracy McMillan	<a href="mailto:tracy.mcmillan2@nhs.net">tracy.mcmillan2@nhs.net</a>
London	Jackie Eastwood	<a href="mailto:jacqueline.eastwood@gstt.nhs.uk">jacqueline.eastwood@gstt.nhs.uk</a>	Daniel Johnson	<a href="mailto:Daniel.Johnson@gstt.nhs.uk">Daniel.Johnson@gstt.nhs.uk</a>
North East and Yorkshire	David Allwood	<a href="mailto:davidallwood@nhs.net">davidallwood@nhs.net</a>	Penny Daynes	<a href="mailto:penny.daynes@nhs.net">penny.daynes@nhs.net</a>
North West	Richard Bateman	<a href="mailto:richard.bateman@liverpoolft.nhs.uk">richard.bateman@liverpoolft.nhs.uk</a>	Andy Stewart	<a href="mailto:Andrew.stewart@liverpoolft.nhs.uk">Andrew.stewart@liverpoolft.nhs.uk</a>
South East	Alison Ashman	<a href="mailto:Alison.Ashman@berkshire.nhs.uk">Alison.Ashman@berkshire.nhs.uk</a>	Melanie Renney	<a href="mailto:melanie.renney@berkshire.nhs.uk">melanie.renney@berkshire.nhs.uk</a>
South West	Danny Palmer	<a href="mailto:danny.palmer@uhbw.nhs.uk">danny.palmer@uhbw.nhs.uk</a>	Natalie Bryson	<a href="mailto:Natalie.Bryson@uhbw.nhs.uk">Natalie.Bryson@uhbw.nhs.uk</a>

### Scotland

[nss.nhssmedicineshortages@nhs.scot](mailto:nss.nhssmedicineshortages@nhs.scot)

### Wales

[MedicinesShortages@gov.wales](mailto:MedicinesShortages@gov.wales)

### Northern Ireland

[RPHPS.Admin@northerntrust.hscni.net](mailto:RPHPS.Admin@northerntrust.hscni.net)

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2025/018

Email: [DHSCmedicinesupplyteam@dhsc.gov.uk](mailto:DHSCmedicinesupplyteam@dhsc.gov.uk).